JP2016522176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522176A5 JP2016522176A5 JP2016509031A JP2016509031A JP2016522176A5 JP 2016522176 A5 JP2016522176 A5 JP 2016522176A5 JP 2016509031 A JP2016509031 A JP 2016509031A JP 2016509031 A JP2016509031 A JP 2016509031A JP 2016522176 A5 JP2016522176 A5 JP 2016522176A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pertuzumab
- variant
- amount
- unpaired cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 43
- 229960002087 pertuzumab Drugs 0.000 claims 37
- 235000018417 cysteine Nutrition 0.000 claims 19
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 19
- 239000013628 high molecular weight specie Substances 0.000 claims 11
- 239000013627 low molecular weight specie Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000012801 analytical assay Methods 0.000 claims 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000005251 capillar electrophoresis Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361812603P | 2013-04-16 | 2013-04-16 | |
| US61/812,603 | 2013-04-16 | ||
| PCT/US2014/034200 WO2014172371A2 (en) | 2013-04-16 | 2014-04-15 | Pertuzumab variants and evaluation thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129841A Division JP2020015719A (ja) | 2013-04-16 | 2019-07-12 | ペルツズマブ変異体及びその評価 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016522176A JP2016522176A (ja) | 2016-07-28 |
| JP2016522176A5 true JP2016522176A5 (enExample) | 2017-06-01 |
Family
ID=50694078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509031A Withdrawn JP2016522176A (ja) | 2013-04-16 | 2014-04-15 | ペルツズマブ変異体及びその評価 |
| JP2019129841A Pending JP2020015719A (ja) | 2013-04-16 | 2019-07-12 | ペルツズマブ変異体及びその評価 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129841A Pending JP2020015719A (ja) | 2013-04-16 | 2019-07-12 | ペルツズマブ変異体及びその評価 |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US9815904B2 (enExample) |
| EP (3) | EP4483964A3 (enExample) |
| JP (2) | JP2016522176A (enExample) |
| KR (2) | KR20200085942A (enExample) |
| CN (1) | CN105121471A (enExample) |
| AR (1) | AR095863A1 (enExample) |
| AU (3) | AU2014254086B2 (enExample) |
| BR (1) | BR112015024926A2 (enExample) |
| CA (2) | CA2907776C (enExample) |
| CL (3) | CL2015003049A1 (enExample) |
| CR (1) | CR20150576A (enExample) |
| EA (1) | EA201591643A1 (enExample) |
| HK (1) | HK1211948A1 (enExample) |
| IL (2) | IL241103B (enExample) |
| MA (1) | MA38567A1 (enExample) |
| MX (2) | MX368259B (enExample) |
| MY (1) | MY173295A (enExample) |
| NZ (2) | NZ712012A (enExample) |
| PE (2) | PE20211214A1 (enExample) |
| PH (1) | PH12015502382A1 (enExample) |
| RU (2) | RU2737727C2 (enExample) |
| SG (3) | SG10201706045RA (enExample) |
| TW (1) | TWI554284B (enExample) |
| WO (1) | WO2014172371A2 (enExample) |
| ZA (1) | ZA201506594B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| TWI472339B (zh) * | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| EP4406615A3 (en) | 2009-10-26 | 2024-12-11 | F. Hoffmann-La Roche AG | Method for the production of a glycosylated immunoglobulin |
| MY194408A (en) | 2011-10-14 | 2022-11-30 | Genentech Inc | Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab |
| TWI554284B (zh) | 2013-04-16 | 2016-10-21 | 建南德克公司 | 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估 |
| JP6914336B2 (ja) * | 2016-12-28 | 2021-08-04 | ジェネンテック， インコーポレイテッド | 進行したｈｅｒ２発現がんの治療 |
| CN117752782A (zh) | 2017-01-17 | 2024-03-26 | 豪夫迈·罗氏有限公司 | 皮下her2抗体配制剂 |
| CN116531511A (zh) | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
| CN110536969A (zh) * | 2017-04-24 | 2019-12-03 | 豪夫迈·罗氏有限公司 | 跨膜或近膜域中的erbb2/her2突变 |
| EP3682249A4 (en) * | 2017-09-13 | 2021-08-25 | Mayo Foundation for Medical Education and Research | IDENTIFICATION AND MONITORING OF ACID HYDROLYSIS PRODUCTS FROM IMMUNOGLOBULIN HEAVY CHAINS |
| JP7259778B2 (ja) | 2020-01-31 | 2023-04-18 | トヨタ自動車株式会社 | 車両、及び自動運転システム |
| EP3892989A1 (en) * | 2020-04-07 | 2021-10-13 | Ares Trading S.A. | Capillary gel electrophoresis and its use with complex biological molecules |
| KR20250151568A (ko) | 2020-06-29 | 2025-10-21 | 제넨테크, 인크. | 퍼투주맙 + 트라스투주맙 고정 용량 조합 |
| CN113999313A (zh) * | 2020-07-28 | 2022-02-01 | 百奥泰生物制药股份有限公司 | 抗her2抗体及其应用 |
| CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
| CN117337195A (zh) | 2021-04-29 | 2024-01-02 | 上海汇连生物医药有限公司 | 抗体偶联药物的制备方法及应用 |
| KR102511384B1 (ko) | 2022-04-14 | 2023-03-16 | 지용환 | 곡물의 손상을 줄일 수 있는 도정기 |
| WO2025021118A1 (zh) * | 2023-07-25 | 2025-01-30 | 海南先声再明医药股份有限公司 | 配体-药物偶联物及其偶联连接子 |
| GB202313175D0 (en) | 2023-08-30 | 2023-10-11 | Univ Oxford Innovation Ltd | A bivalent polypeptide scaffold and uses thereof |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| CA2055441C (en) | 1989-05-19 | 2003-01-07 | Robert M. Hudziak | Her2 extracellular domain |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| DE69739673D1 (de) | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| WO1999048527A1 (en) | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| ES2292682T3 (es) | 1998-05-06 | 2008-03-16 | Genentech, Inc. | Purificacion de anticuerpos mediante cromatografia de intercambio ionico. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| DK1187632T3 (da) | 1999-05-14 | 2009-04-06 | Genentech Inc | Behandling med anti-ErbB2-antistoffer |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| CN100381172C (zh) | 1999-06-25 | 2008-04-16 | 吉尼泰克公司 | 使用抗-ErbB2抗体治疗前列腺癌 |
| US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
| US20200048362A1 (en) | 2000-03-16 | 2020-02-13 | Immunogen, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| PT1282443E (pt) | 2000-05-19 | 2009-12-04 | Genentech Inc | Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| JP4731793B2 (ja) | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| PT1358318E (pt) * | 2001-02-07 | 2007-01-31 | Wilex Ag | Linha celular de hibridoma g250 e sua utilização para produção de anticorpos monoclonais |
| CA2481515C (en) | 2002-04-10 | 2013-10-01 | Genentech, Inc. | Anti-her2 antibody variants |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| EP2263691B1 (en) | 2002-07-15 | 2012-08-29 | F.Hoffmann-La Roche Ag | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) |
| CA2496060C (en) | 2002-09-11 | 2015-08-04 | Genentech, Inc. | Protein purification by ion exchange chromatography |
| HK1078613A1 (zh) | 2002-11-21 | 2006-03-17 | Genentech, Inc. | 通过抗-erbb2抗体医治非恶性疾病或病患的疗法 |
| US20050163782A1 (en) | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| PT3095793T (pt) | 2003-07-28 | 2020-05-04 | Genentech Inc | Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a |
| WO2005099756A2 (en) | 2004-04-08 | 2005-10-27 | Agus David B | ErbB ANTAGONISTS FOR PAIN THERAPY |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| KR20110050567A (ko) | 2004-07-22 | 2011-05-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| US20060067930A1 (en) | 2004-08-19 | 2006-03-30 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US20060121044A1 (en) | 2004-12-07 | 2006-06-08 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| EP1827603A2 (en) | 2004-12-13 | 2007-09-05 | F. Hoffmann-Roche AG | Novel pharmaceutical composition containing at least one dolastatin 10 derivative |
| UA94899C2 (ru) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| DK1850874T3 (da) | 2005-02-23 | 2013-11-11 | Genentech Inc | Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab |
| WO2006096861A2 (en) | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| BRPI0712077A2 (pt) | 2006-05-01 | 2012-01-17 | Genentech Inc | prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa |
| US8015939B2 (en) | 2006-06-30 | 2011-09-13 | Asml Netherlands B.V. | Imprintable medium dispenser |
| BRPI0715829A2 (pt) | 2006-08-21 | 2013-07-23 | Hoffmann La Roche | terapia de tumor com um anticorpo anti-vegf |
| WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| BRPI0808418A2 (pt) | 2007-03-02 | 2014-07-22 | Genentech, Inc | Predição de resposta a um inibidor de her |
| RU2500686C2 (ru) | 2007-03-22 | 2013-12-10 | Дженентек, Инк. | АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE |
| EP1997534A1 (en) | 2007-05-31 | 2008-12-03 | Pierre Fabre Medicament | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
| CA2687819A1 (en) | 2007-06-06 | 2008-12-11 | F.Hoffmann-La Roche Ag | Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label |
| ES2583377T3 (es) | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| MX354993B (es) | 2007-07-09 | 2018-03-28 | Genentech Inc | Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos. |
| CA2699202C (en) | 2007-09-12 | 2016-09-27 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| CA2698541C (en) | 2007-10-19 | 2018-01-09 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| BRPI0817182A2 (pt) | 2007-10-30 | 2015-03-17 | Genentech Inc | Método para purificar um anticorpo e composições |
| JP2011511777A (ja) * | 2008-01-30 | 2011-04-14 | アボット・ラボラトリーズ | 抗体断片を結晶化するための組成物及び方法 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| WO2009111707A1 (en) | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| HUE035184T2 (en) | 2008-03-18 | 2018-05-02 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| US9235334B2 (en) | 2008-05-09 | 2016-01-12 | Genesis Industries, Llc | Managing landbases and machine operations performed thereon |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| FR2942799B1 (fr) * | 2009-03-06 | 2011-02-25 | Lfb Biotechnologies | Anticorps monoclonal anti-rhesus d |
| SG176073A1 (en) | 2009-05-29 | 2011-12-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2011069074A2 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| CA2782571C (en) * | 2009-12-22 | 2018-01-23 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| MX2013006392A (es) | 2010-12-09 | 2013-12-06 | Genentech Inc | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| ES2746559T3 (es) * | 2011-01-28 | 2020-03-06 | Nat Res Council Canada | Modificación genética de dominios de inmunoglobulina |
| EP2683413A1 (en) | 2011-03-07 | 2014-01-15 | F.Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
| MY194408A (en) | 2011-10-14 | 2022-11-30 | Genentech Inc | Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab |
| EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
| KR101915942B1 (ko) | 2012-06-08 | 2018-11-06 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
| JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定 |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| TWI554284B (zh) | 2013-04-16 | 2016-10-21 | 建南德克公司 | 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估 |
| NZ760065A (en) | 2013-12-17 | 2022-12-23 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| RU2020120593A (ru) | 2014-04-25 | 2020-09-01 | Дженентек, Инк. | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| WO2018085513A1 (en) | 2016-11-04 | 2018-05-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック， インコーポレイテッド | 進行したｈｅｒ２発現がんの治療 |
| CN117752782A (zh) | 2017-01-17 | 2024-03-26 | 豪夫迈·罗氏有限公司 | 皮下her2抗体配制剂 |
| CN116531511A (zh) | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
| EP3858333B1 (en) | 2017-10-20 | 2025-11-26 | BioNTech SE | Preparation and storage of liposomal rna formulations suitable for therapy |
| KR20250151568A (ko) | 2020-06-29 | 2025-10-21 | 제넨테크, 인크. | 퍼투주맙 + 트라스투주맙 고정 용량 조합 |
| WO2022013189A1 (en) | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Assays for fixed dose combinations |
| WO2022125483A1 (en) | 2020-12-11 | 2022-06-16 | Genentech, Inc. | Combination therapies for treatment of her2 cancer |
| TW202400230A (zh) | 2022-03-14 | 2024-01-01 | 美商建南德克公司 | 乳癌的組合療法 |
-
2014
- 2014-04-15 TW TW103113741A patent/TWI554284B/zh active
- 2014-04-15 CA CA2907776A patent/CA2907776C/en active Active
- 2014-04-15 BR BR112015024926A patent/BR112015024926A2/pt not_active Application Discontinuation
- 2014-04-15 MX MX2015013898A patent/MX368259B/es active IP Right Grant
- 2014-04-15 SG SG10201706045RA patent/SG10201706045RA/en unknown
- 2014-04-15 SG SG10201911353WA patent/SG10201911353WA/en unknown
- 2014-04-15 US US14/253,038 patent/US9815904B2/en active Active
- 2014-04-15 NZ NZ712012A patent/NZ712012A/en unknown
- 2014-04-15 EP EP24211694.5A patent/EP4483964A3/en active Pending
- 2014-04-15 EA EA201591643A patent/EA201591643A1/ru unknown
- 2014-04-15 SG SG11201508536PA patent/SG11201508536PA/en unknown
- 2014-04-15 AU AU2014254086A patent/AU2014254086B2/en active Active
- 2014-04-15 CN CN201480020921.2A patent/CN105121471A/zh active Pending
- 2014-04-15 HK HK15112673.2A patent/HK1211948A1/xx unknown
- 2014-04-15 WO PCT/US2014/034200 patent/WO2014172371A2/en not_active Ceased
- 2014-04-15 CA CA3071678A patent/CA3071678A1/en not_active Abandoned
- 2014-04-15 AR ARP140101600A patent/AR095863A1/es unknown
- 2014-04-15 NZ NZ751877A patent/NZ751877A/en unknown
- 2014-04-15 KR KR1020207019835A patent/KR20200085942A/ko not_active Ceased
- 2014-04-15 PE PE2021000128A patent/PE20211214A1/es unknown
- 2014-04-15 EP EP14723656.6A patent/EP2986643A2/en not_active Withdrawn
- 2014-04-15 KR KR1020157032283A patent/KR20150143649A/ko not_active Ceased
- 2014-04-15 PE PE2015002163A patent/PE20151769A1/es unknown
- 2014-04-15 RU RU2015141520A patent/RU2737727C2/ru active
- 2014-04-15 MA MA38567A patent/MA38567A1/fr unknown
- 2014-04-15 JP JP2016509031A patent/JP2016522176A/ja not_active Withdrawn
- 2014-04-15 RU RU2019115089A patent/RU2019115089A/ru unknown
- 2014-04-15 EP EP20201975.8A patent/EP3800204A1/en not_active Withdrawn
- 2014-04-15 MY MYPI2015002532A patent/MY173295A/en unknown
-
2015
- 2015-09-03 IL IL241103A patent/IL241103B/en active IP Right Grant
- 2015-09-07 ZA ZA2015/06594A patent/ZA201506594B/en unknown
- 2015-10-01 MX MX2019005151A patent/MX2019005151A/es unknown
- 2015-10-14 PH PH12015502382A patent/PH12015502382A1/en unknown
- 2015-10-15 CL CL2015003049A patent/CL2015003049A1/es unknown
- 2015-10-15 CR CR20150576A patent/CR20150576A/es unknown
-
2017
- 2017-09-28 CL CL2017002445A patent/CL2017002445A1/es unknown
- 2017-10-19 US US15/788,632 patent/US20180037662A1/en not_active Abandoned
- 2017-10-19 US US15/788,598 patent/US20180037661A1/en not_active Abandoned
- 2017-10-19 US US15/788,574 patent/US9969811B2/en active Active
-
2018
- 2018-10-05 AU AU2018241141A patent/AU2018241141B2/en active Active
-
2019
- 2019-07-12 US US16/510,287 patent/US20190345258A1/en not_active Abandoned
- 2019-07-12 JP JP2019129841A patent/JP2020015719A/ja active Pending
- 2019-08-06 US US16/533,488 patent/US20200157238A1/en not_active Abandoned
- 2019-08-08 CL CL2019002244A patent/CL2019002244A1/es unknown
- 2019-10-22 AU AU2019253804A patent/AU2019253804A1/en not_active Abandoned
-
2020
- 2020-06-15 IL IL275398A patent/IL275398A/en unknown
-
2022
- 2022-06-27 US US17/809,098 patent/US12145998B2/en active Active
-
2024
- 2024-10-14 US US18/914,687 patent/US20250084181A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522176A5 (enExample) | ||
| RU2015141520A (ru) | Варианты пертузумаба и их аналитическая характеристика | |
| US11208498B2 (en) | Treatment and prevention of cancer using HER3 antigen-binding molecules | |
| US20240092937A1 (en) | Her3 antigen-binding molecules | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| CN107847595A (zh) | 特异性针对过度磷酸化τ蛋白的抗体及其使用方法 | |
| BRPI0717363B8 (pt) | imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| MX2011012039A (es) | Anticuerpos bloqueadores anti-dkk-1 y sus usos. | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| EP2543727A4 (en) | MODIFIED ANTIBODY COMPOSITION | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| MX2009009379A (es) | Metodos y composiciones para tratar enfermedades tumorales. | |
| JP6033459B2 (ja) | Ｂｍｐ−６抗体 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| JP2023549067A (ja) | Ｓａｒｓ－ｃｏｖ－２に対する抗体およびその使用 | |
| MX2025002112A (es) | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| MX340350B (es) | Proteinas de union a antigeno especificas para el componente p amiloide serico. | |
| WO2016168634A1 (en) | Biomarkers related to treatment of cancer with her3 and egfr inhibitors | |
| WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
| JP2019531254A5 (enExample) | ||
| US20210388083A1 (en) | Engineered fc | |
| BR122025020609A2 (pt) | Anticorpos antagonistas isolados que se ligam especificamente a pd-1 ou porção de ligação ao antígeno dos mesmos, seus métodos de produção, seus usos, composições farmacêuticas, polinucleotídeos, vetores, células hospedeiras, anticorpo anti-idiotípico e kit |